Developing Allosteric Chaperones for GBA1-Associated Disorders—An Integrated Computational and Experimental Approach

Mutations in the <i>GBA1</i> gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase), are associated with Gaucher disease and increased risk of Parkinson's disease. This study describes the discovery and characterization of novel allosteric pharmacological chaperones for GCase through an innovative computational approach combined with experimental validation. Utilizing virtual screening and structure-activity relationship optimization, researchers identified several compounds that significantly enhance GCase activity and stability across various cellular models, including patient-derived fibroblasts and neuronal cells harboring <i>GBA1</i> mutations. Among these, compound <b>3</b> emerged as a lead candidate, demonstrating the ability to enhance GCase protein levels and enzymatic activity while effectively reducing the accumulation of toxic substrates in neuronal models. Importantly, pharmacokinetic studies revealed that compound <b>3</b> has favorable brain penetration, indicating its potential as a disease-modifying therapy for <i>GBA1</i>-related disorders affecting the central nervous system. This research not only offers a framework for developing allosteric GCase modulators but also unveils promising new therapeutic strategies for managing Gaucher disease and Parkinson's disease. The ability of compound <b>3</b> to cross the blood-brain barrier emphasizes its potential significance in addressing neurological symptoms associated with these conditions.